Vistagen Therapeutics Stock Today
| VTGN Stock | USD 2.09 0.13 6.63% |
PerformanceVery Weak
| Odds Of DistressLow
|
VistaGen Therapeutics is selling at 2.09 as of the 25th of June 2025; that is 6.63 percent increase since the beginning of the trading day. The stock's open price was 1.96. VistaGen Therapeutics has only a 6 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 26th of May 2025 and ending today, the 25th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of May 2016 | Category Healthcare | Classification Health Care |
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system . VistaGen Therapeutics, Inc. The company has 29.16 M outstanding shares of which 533.81 K shares are at this time shorted by private and institutional investors with about 3.69 trading days to cover. More on VistaGen Therapeutics
Moving together with VistaGen Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
VistaGen Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Shawn JD | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Nasdaq Industrial, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsVistaGen Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand VistaGen Therapeutics' financial leverage. It provides some insight into what part of VistaGen Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
VistaGen Therapeutics (VTGN) is traded on NASDAQ Exchange in USA. It is located in 343 Allerton Avenue, South San Francisco, CA, United States, 94080 and employs 56 people. VistaGen Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 60.94 M. VistaGen Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29.16 M outstanding shares of which 533.81 K shares are at this time shorted by private and institutional investors with about 3.69 trading days to cover.
VistaGen Therapeutics currently holds about 51.99 M in cash with (42.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25.
Check VistaGen Therapeutics Probability Of Bankruptcy
Ownership AllocationVistaGen Therapeutics shows a total of 29.16 Million outstanding shares. Over half of VistaGen Therapeutics' outstanding shares are owned by institutional holders. These institutional holders are typically referred to as corporate investors that take positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check VistaGen Ownership Details
VistaGen Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2025-03-31 | 270.2 K | |
| Almitas Capital Llc | 2025-03-31 | 254.7 K | |
| Boothbay Fund Management, Llc | 2025-03-31 | 177.9 K | |
| Advisorshares Investments, Llc | 2025-03-31 | 159.1 K | |
| Bml Capital Management Llc | 2025-03-31 | 150 K | |
| Ubs Group Ag | 2024-12-31 | 132.3 K | |
| Persistent Asset Partners Limited | 2025-03-31 | 121.7 K | |
| Two Sigma Investments Llc | 2025-03-31 | 112.5 K | |
| Blair William & Co | 2025-03-31 | 100.9 K | |
| Tcg Crossover Management, Llc | 2025-03-31 | 2.7 M | |
| Stempoint Capital Lp | 2025-03-31 | 2.4 M |
VistaGen Therapeutics Historical Income Statement
VistaGen Stock Against Markets
VistaGen Therapeutics Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Michelle Wellington | Vice Communications | Profile | |
| Cynthia CPA | Chief Officer | Profile | |
| Mark Ginski | Manufacturing Chemistry | Profile | |
| Erik MD | Senior Pharmacovigilance | Profile | |
| JD Esq | Chief Officer | Profile | |
| Louis MD | Senior Neuroscience | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VistaGen Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in VistaGen Stock, please use our How to Invest in VistaGen Therapeutics guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VistaGen Therapeutics. If investors know VistaGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VistaGen Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share | Quarterly Revenue Growth (0.43) | Return On Assets | Return On Equity |
The market value of VistaGen Therapeutics is measured differently than its book value, which is the value of VistaGen that is recorded on the company's balance sheet. Investors also form their own opinion of VistaGen Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VistaGen Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VistaGen Therapeutics' market value can be influenced by many factors that don't directly affect VistaGen Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VistaGen Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VistaGen Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VistaGen Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.